Updates to BC-CfE HIV Drug Treatment and Prevention Programs

  • Formulary Addition: Dolutegravir-lamivudine (Dovato®)
  • Resumption of routine HIV plasma viral load testing
  • Updates to BC-CfE Guidance Documents
Scroll to Top

The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025